These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17571441)

  • 1. Anti-HIV agents. Maraviroc--absorption and drug-interaction issues.
    TreatmentUpdate; 2007; 19(3):5. PubMed ID: 17571441
    [No Abstract]   [Full Text] [Related]  

  • 2. When and how to use maraviroc in HIV-infected patients.
    Soriano V; Perno CF; Kaiser R; Calvez V; Gatell JM; di Perri G; Pillay D; Rockstroh J; Geretti AM
    AIDS; 2009 Nov; 23(18):2377-85. PubMed ID: 19834318
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-HIV agents. Maraviroc in treatment-experienced PHAs.
    TreatmentUpdate; 2006; 18(4):5. PubMed ID: 17205654
    [No Abstract]   [Full Text] [Related]  

  • 4. Two new drugs for HIV infection.
    Med Lett Drugs Ther; 2008 Jan; 50(1277):2-4. PubMed ID: 18197163
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral administration of the CCR5 inhibitor, maraviroc, blocks HIV ex vivo infection of Langerhans cells within the epithelium.
    Matsuzawa T; Kawamura T; Ogawa Y; Takahashi M; Aoki R; Moriishi K; Koyanagi Y; Gatanaga H; Blauvelt A; Shimada S
    J Invest Dermatol; 2013 Dec; 133(12):2803-2805. PubMed ID: 23648547
    [No Abstract]   [Full Text] [Related]  

  • 6. An in-depth look at the challenges of prescribing maraviroc.
    Edmunds-Ogbuokiri T
    HIV Clin; 2008; 20(3):9-11. PubMed ID: 18814378
    [No Abstract]   [Full Text] [Related]  

  • 7. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
    Schapiro JM; Boucher CA; Kuritzkes DR; van de Vijver DA; Llibre JM; Lewis M; Simpson P; Delogne C; McFadyen L; Chapman D; Perros M; Valdez H; van der Ryst E; Westby M
    Antivir Ther; 2011; 16(3):395-404. PubMed ID: 21555822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA notifications. Maraviroc approved as a CCR5 co-receptor antagonist.
    AIDS Alert; 2007 Sep; 22(9):103. PubMed ID: 18411462
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical pharmacokinetic of maraviroc].
    Peytavin G
    Med Mal Infect; 2008 Mar; 38 Suppl 1():S12-6. PubMed ID: 18455057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Something new under the sun. Maraviroc poised for approval.
    Huff B
    GMHC Treat Issues; 2006; 20(8-12):1-4. PubMed ID: 17569160
    [No Abstract]   [Full Text] [Related]  

  • 11. Interactions between alcohol and the HIV entry inhibitor Maraviroc.
    Gruber VA; Rainey PM; Lum PJ; Beatty GW; Aweeka FT; McCance-Katz EF
    J Int Assoc Provid AIDS Care; 2013; 12(6):375-7. PubMed ID: 23881910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Maraviroc efficacy in clinical studies on the development of the molecule].
    Moreno S; Hernández B; Gutiérrez C; Delsol E
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():17-22. PubMed ID: 19133217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. It's official...but not infallible.
    Prescrire Int; 2010 Nov; 19(110):244. PubMed ID: 21284352
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment. Maraviroc dosing not effective in half of blacks.
    AIDS Policy Law; 2014 Oct; 29(11):1. PubMed ID: 25330547
    [No Abstract]   [Full Text] [Related]  

  • 15. A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients.
    D'Avolio A; Simiele M; Baietto L; Siccardi M; Sciandra M; Patanella S; Bonora S; Di Perri G
    Ther Drug Monit; 2010 Feb; 32(1):86-92. PubMed ID: 20040898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of HIV infection with the CCR5 antagonist maraviroc.
    Kromdijk W; Huitema AD; Mulder JW
    Expert Opin Pharmacother; 2010 May; 11(7):1215-23. PubMed ID: 20402558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Conclusions and perspectives. Maraviroc].
    Alcamí J
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():49-54. PubMed ID: 19133222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel HIV treatment approved.
    Groeschen HM
    Am J Health Syst Pharm; 2007 Sep; 64(18):1886. PubMed ID: 17823091
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-HIV agents. Maraviroc and resistance.
    TreatmentUpdate; 2007; 19(6):4-5. PubMed ID: 18041148
    [No Abstract]   [Full Text] [Related]  

  • 20. The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects.
    Chan PL; Jacqmin P; Lavielle M; McFadyen L; Weatherley B
    J Pharmacokinet Pharmacodyn; 2011 Feb; 38(1):41-61. PubMed ID: 21088872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.